CytoDyn Joins Clients of Mike Orshan after His Departure as Director of New Mexico's Office of Science and Technology.

SANTA FE, N.M. -- CytoDyn, Inc. (OTCBB:CYDY) has joined the clients of Mike Orshan's new company, T2B, after Orshan's departure as the Director of Science and Technology for New Mexico's Economic Development Department. During his two-and-a-half year stint with the State of New Mexico, Orshan worked to advance cooperation between universities, research laboratories, venture capitalists, and high-tech companies.

"This is part and parcel of our effort to commercialize scientific advances, which we are pursuing at an international level through other strategic alliances," CytoDyn CEO Allen D. Allen said. "Our long-term goal is to have a state-of-the-art manufacturing facility in New Mexico," Allen added. "In the meantime," Allen continued, "we hope to use our advanced immunological knowledge to provide better and safer vaccines, and to overcome the problems that have plagued gene research, in the immediate future."

Allen points out that the scientific literature explaining why only humans develop a disease in response to HIV infection dates back 15 years. Selected references are available at www.cytodyn.com/hx_cytolin.htm. In preliminary clinical trials, application of this knowledge reduced viral burden by using the host's immune system to control the infection, thereby avoiding the problem of multi-drug resistant strains of HIV, as well as the side effects of the antiretroviral drugs.

Likewise, neuroimmunological research conducted by Allen and colleagues in the late 1980s has yet to be applied to prevent the immune system from responding to vaccines with hypersensitivity reactions, famously including the Guillain-Barre syndrome that afflicted over 500 individuals vaccinated with influenza A/New Jersey/76 (swine flu) with 25 reported fatalities during the Ford administration.

Forward-looking statements are statements that are not historical facts. As in this press release, CytoDyn's management makes forward-looking statements concerning the Company's expected future operations, performance and other developments. These forward-looking statements are necessarily estimates based upon current information and involve a number of risks and uncertainties. There can be no assurance that such risks and uncertainties, or other factors, will not affect the accuracy of such forward-looking statements. It is impossible to identify all factors that could cause actual results to differ materially from those estimated by the Company. They include, but are not limited to, government regulation, managing and maintaining growth, victimization by white-collar offenders, and the effects of adverse publicity, litigation, competition, and other factors that may be identified from time to time in the Company's announcements.